136 related articles for article (PubMed ID: 7519650)
1. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
Bosl GJ; Head MD
Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
[TBL] [Abstract][Full Text] [Related]
2. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
3. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
5. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
6. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
7. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
8. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
10. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
13. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
de Wit R; Collette L; Sylvester R; de Mulder PH; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Stoter G
Br J Cancer; 1998 Nov; 78(10):1350-5. PubMed ID: 9823978
[TBL] [Abstract][Full Text] [Related]
14. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
15. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.
Kawaguchi T; Kumabe T; Kanamori M; Saito R; Yamashita Y; Sonoda Y; Watanabe M; Tominaga T
J Neurooncol; 2011 Sep; 104(3):779-87. PubMed ID: 21359564
[TBL] [Abstract][Full Text] [Related]
16. Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis--clinical implications.
Otto T; Virchow S; Fuhrmann C; Steinberg F; Streffer C; Goepel M; Rübben H
Urol Res; 1997; 25(2):121-4. PubMed ID: 9144879
[TBL] [Abstract][Full Text] [Related]
17. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
Davis BE; Herr HW; Fair WR; Bosl GJ
J Urol; 1994 Jul; 152(1):111-3; discussion 114. PubMed ID: 7515445
[TBL] [Abstract][Full Text] [Related]
18. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
20. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
Che Y; Buddensieck C; Albers P; Lusch A; Winter C; Siemer RG; Hiester A
J Urol; 2022 Mar; 207(3):617-626. PubMed ID: 34694152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]